Immunai is a biotechnology company that develops single-cell immune profiling and computational platforms to map the human immune system. The company combines high-throughput single-cell assays, multi-omic data integration, and machine-learning analytics to identify immune cell states, biomarkers, and therapeutic targets for drug discovery and translational research partnerships.
Estimated Valuation
Powered by
Leadership & Board
- Current Number of Employees
- 171
- Current LinkedIn Followers
- 29,002
Latest Estimated Valuation
- Total Amount Raised
- $215M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $215M
- Latest Funding Round
- Series B
Employee Trend
Immunai had 171 employees as of October 26, 2026. The number of employees increased by 0 (0.00%) week-over-week.
171Latest Employee Count
0(0.00%)Week-Over-Week Change
Social Trend
Immunai had 29,002 followers as of October 26, 2026. The number of followers increased by 77 (0.27%) week-over-week.
29,002Latest Followers Count
77(0.27%)Week-Over-Week Change
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Nov 27, 2021 | Series B | $215.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Koch Disruptive Technologies | Series B |
Similar Companies
A snapshot of private companies similar to Immunai, helping you discover and navigate related company profiles.
Related News and Analysis
